Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial

IMPORTANCE: Perioperative chemotherapy and surgery are a standard of care for operable gastroesophageal adenocarcinoma. Anti-HER2 therapy improves survival in patients with advanced HER2-positive disease. The safety and feasibility of adding lapatinib to perioperative chemotherapy should be assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Smyth, Elizabeth C., Rowley, Samuel, Cafferty, Fay H., Allum, William, Grabsch, Heike I., Stenning, Sally, Wotherspoon, Andrew, Alderson, Derek, Crosby, Tom, Mansoor, Was, Waters, Justin S., Neville-Webbe, Helen, Darby, Suzanne, Dent, Jo, Seymour, Matthew, Thompson, Joyce, Sothi, Sharmila, Blazeby, Jane, Langley, Ruth E., Cunningham, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587151/
https://www.ncbi.nlm.nih.gov/pubmed/31219517
http://dx.doi.org/10.1001/jamaoncol.2019.1179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587151/
https://www.ncbi.nlm.nih.gov/pubmed/31219517
http://dx.doi.org/10.1001/jamaoncol.2019.1179

Ejemplares similares